Carelabs Co Ltd

Carelabs has a liquidity position that is relatively strong, with cash and equivalents amounting to KRW 24,456,500,750, which is 27.9% of its total assets. However, the company's long-term debt of KRW 57,971,856,820 exceeds its cash reserves, resulting in a negative net cash position. The debt-to-equity ratio of 0.82 suggests a moderate level of leverage, while the current ratio of 3.22 indicates that the company has sufficient short-term assets to cover its liabilities.

Profitability metrics for Carelabs are mixed. The company reported a net loss of KRW 558,854,390, and its return on equity (ROE) is negative at -0.79%. This is significantly below the industry median for health care technology firms, which typically report positive ROE. The operating margin is also weak, with operating income of KRW 324,114,760 on total revenue of KRW 22,363,998,830, translating to a margin of 1.45%. This is below the industry median of 10.2% for comparable firms.

Geographically, Carelabs' revenue is concentrated in a single market, with no disclosed international operations. The company's business is entirely dependent on its domestic market, which increases its exposure to local economic and regulatory risks. There are no disclosed segments or product lines, making it difficult to assess diversification within the business.

The company's growth trajectory is uncertain. Revenue for the latest period was KRW 22,363,998,830, but there is no historical data provided to assess year-over-year growth. The free cash flow of KRW 573,263,430 is positive, but the operating cash flow is negative at KRW -204,454,170, indicating that the company is not generating sufficient cash from operations to sustain its activities. The capital expenditure of KRW -56,186,090 suggests some level of investment in the business, but the overall cash flow picture is mixed.

Risk factors for Carelabs include its negative net cash position and the potential for dilution, although the risk of dilution is currently assessed as low. The company has a medium liquidity risk due to its reliance on cash reserves to service its debt. There are no recent filings or transcripts provided to assess management commentary or strategic direction.

Recent events and disclosures are limited, with no specific filings or transcripts provided. The company's financial performance and strategic direction remain opaque without additional information from management or regulatory filings.

Net income surged 194.6% year-over-year to 19.2 billion KRW, marking a significant profitability turnaround from prior losses.

Free cash flow improved by 129.6% to 5.6 billion KRW, demonstrating a strong recovery in cash generation capabilities.

Long-term debt decreased substantially to 11.0 billion KRW, significantly reducing leverage compared to the 74.9 billion KRW peak in 2022.

Operating income turned positive at -2.9 billion KRW, representing a 73.2% improvement and signaling operational stabilization.

Gross profit remained robust at 80.1 billion KRW, indicating that core revenue generation remains strong despite net income volatility.

The company faces high credit risk, posing a significant threat to financial stability and potential default on obligations.

Debt-to-equity ratio of 0.82 is in the bottom quartile of the software cohort, indicating higher financial leverage than peers.

Revenue KRW 87.61B, −6,7% YoY; Operating income −1 617,0% YoY.

• ▍Revenue KRW 87.61B, −6,7% YoY
• ▍Operating income −1 617,0% YoY
• ▍Net income −2 185,1% YoY
• ▍Free cash flow −7 075,6% YoY
• ▍Net margin -29.8%

Revenue KRW 93.93B; Operating income KRW 1.15B.

• ▍Revenue KRW 93.93B
• ▍Operating income KRW 1.15B
• ▍Net margin 1.3%